Back

Aberrant immune regulation and enrichment of stem-like CD8+ T cells in the pancreatic lymph node during type 1 diabetes development

Peters, L. D.; Seay, H. R.; Smith, J. A.; Posgai, A. L.; Berkowitz, R. L.; Wasserfall, C. H.; Atkinson, M. A.; Bacher, R.; Brusko, M. A.; Brusko, T. M.

2026-04-01 immunology
10.1101/2025.05.23.655848 bioRxiv
Show abstract

Effector CD8+ T cells are key cellular drivers of type 1 diabetes (T1D) pathogenesis, yet questions remain regarding the molecular defects leading to altered cytotoxicity, their signature in peripheral tissues, and their receptor specificity. Thus, we analyzed human pancreatic lymph nodes (pLN) using mass cytometry and single cell RNA sequencing (scRNAseq) with combined proteomic and T cell receptor (TCR) profiling. Cytometric analysis revealed an enriched population of T stem-cell memory (TSCM)-like cells (CD8+CD45RA+CD27+CD28+CCR7+CXCR3+ T cells) in T1D pLNs. scRNAseq profiling indicated an elevated inflammatory cytokine gene signature (IFITM3, LTB) along with regulators of terminal differentiation (BCL6, BCL3), coupled with reduced expression of exhaustion-associated genes (DUSP2, NR4A2, TSC22D3) in CD8+ T cells in T1D pLN. Additionally, effector CD8+ T cells expressed features of progenitor exhausted cells (BCL2) in T1D pLN. Immune Response Enrichment Analysis (IREA) indicated IL-15 signaling as a significant driver of these phenotypes. Integrated TCR and transcriptomic analysis revealed a cluster of diverse naive-like CD8+ T cell clones in T1D pLN. When comparing pLN and pancreatic slice cellular isolates, we observed sharing of effector CD8+ T cells, with upregulation of terminal effector signatures detected within the pancreas relative to paired pLN samples. Multiplex imaging revealed differential localization of TCF1 and TOX expressing T cells in the pancreas, with TCF1+TOX+ cells located in closer proximity to the islets and displaying a mixture of activation and exhaustion-associated phenotypes. Thus, we provide multimodal cellular profiles enriched in T1D tissues for consideration in therapeutic targeting.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Diabetes
53 papers in training set
Top 0.1%
10.6%
2
Cell Reports
1338 papers in training set
Top 4%
8.5%
3
JCI Insight
241 papers in training set
Top 0.4%
6.9%
4
Nature Communications
4913 papers in training set
Top 28%
6.5%
5
Frontiers in Immunology
586 papers in training set
Top 1%
4.9%
6
Gastroenterology
40 papers in training set
Top 0.4%
4.9%
7
Journal of Clinical Investigation
164 papers in training set
Top 0.9%
3.7%
8
eBioMedicine
130 papers in training set
Top 0.3%
3.6%
9
Cell Reports Medicine
140 papers in training set
Top 2%
3.1%
50% of probability mass above
10
Gut
36 papers in training set
Top 0.3%
2.5%
11
Immunity
58 papers in training set
Top 2%
2.1%
12
Cell Metabolism
49 papers in training set
Top 0.9%
1.9%
13
Nature Immunology
71 papers in training set
Top 1.0%
1.9%
14
Diabetologia
36 papers in training set
Top 0.5%
1.8%
15
Cellular & Molecular Immunology
14 papers in training set
Top 0.8%
1.7%
16
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.5%
17
eLife
5422 papers in training set
Top 47%
1.3%
18
Genome Medicine
154 papers in training set
Top 6%
1.2%
19
Scientific Reports
3102 papers in training set
Top 66%
1.2%
20
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.0%
21
Molecular Metabolism
105 papers in training set
Top 1%
0.9%
22
Science Translational Medicine
111 papers in training set
Top 6%
0.8%
23
Journal of Hepatology
18 papers in training set
Top 0.3%
0.8%
24
The Journal of Immunology
146 papers in training set
Top 2%
0.7%
25
iScience
1063 papers in training set
Top 37%
0.7%
26
Cell Death & Differentiation
48 papers in training set
Top 1.0%
0.7%
27
Science Immunology
81 papers in training set
Top 2%
0.7%
28
Cell Death & Disease
126 papers in training set
Top 3%
0.7%
29
Life Science Alliance
263 papers in training set
Top 2%
0.7%
30
BMC Medicine
163 papers in training set
Top 9%
0.5%